Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.39 |
| ▸ | WNT3A | P56704 | 4/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403235 | 0.78 | CTNNB1 (0.37) | CTNNB1WNT3AADRB3MRGPRX4MEN1 | |
| SCHEMBL6400319 | 0.75 | MMP2 (0.39) | CTNNB1WNT3AADRB3MRGPRX4MEN1 | |
| SCHEMBL6399715 | 0.75 | MMP2 (0.39) | CTNNB1WNT3AADRB3MRGPRX4MEN1 | |
| SCHEMBL6605788 | 0.74 | PTPRB (0.42) | MEN1KMT2ACA12 | |
| SCHEMBL6605782 | 0.74 | PTPRB (0.42) | MEN1KMT2ACA12 | |
| SCHEMBL6605239 | 0.71 | CYP2A6 (0.46) | CTNNB1WNT3AADRB3MRGPRX4MEN1 | |
| SCHEMBL6605234 | 0.71 | CYP2A6 (0.46) | CTNNB1WNT3AADRB3MRGPRX4MEN1 | |
| SCHEMBL6406210 | 0.70 | CA2 (0.38) | CTNNB1WNT3AADRB3MRGPRX4CYP2A6 | |
| SCHEMBL6406203 | 0.70 | CA2 (0.38) | CTNNB1WNT3AADRB3MRGPRX4CYP2A6 | |
| SCHEMBL6401305 | 0.70 | PTPRB (0.40) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | CTNNB1 2821/4885WNT3A 2202/4885ADRB3 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.